Home Sectors Healthcare Buy or Sell: Charles River Laboratories International (NYSE: CRL)

Buy or Sell: Charles River Laboratories International (NYSE: CRL)


Charles River Laboratories International is in the healthcare sector and is part of the medical diagnostics and research industry. The company CEO is James C. Foster. Charles River Laboratories International Inc is a pharmaceutical company providing drug discovery and development services. The company provides animal models for laboratory testing, and offers manufacturing testing services to various industries.

Previous Intraday Trading Performance:

The CRL stock showed a previous change of 2.53% with an open at 124.64 and a close of 126.52. It reached an intraday high of 126.61 and a low of 123.89.

Business Wire:  Charles River Laboratories to Present at Jefferies and Goldman Sachs Investor Conferences


The stock has a market cap of $6.2b with 48.8m shares outstanding, of which the float is 46.9m shares. Trading volume reached 288,100 shares compared to its average volume of 381,875 shares. Based on the current average volume and close price, the trading liquidity is good.

Historical Trading Performance:

Over the last five trading days, Charles River Laboratories International shares returned 0.80% and in the past 30 trading days it returned -7.00%. Over three months, it changed -10.40%. In one year it has changed 16.05% and within that year its 52-week high was 149.07 and its 52-week low was 103.00. CRL stock is 22.83% above its 52 Week Low.

Our calculations show a 200 day moving average of 129.77 and a 50 day moving average of 137.04. Currently CRL stock is trading -2.50% below its 200 day moving average and may be a good opportunity to buy, but should check other indicators to confirm a buy signal.

Business Wire:  Charles River Laboratories to Present at Jefferies and Goldman Sachs Investor Conferences


The last annual fiscal EPS for the company was reported at 4.63 that ended on 31st of December 2018, which according to the previous close, that is a PE of 27.33. Based on 10 analyst estimates, the consensus EPS for the next quarter is 1.38. The TTM EPS is 6.02, which comes to a TTM PE of 21.02. Historically, the PE high was 54.80 and the PE low was 21.00. If the stock reached its PE low, that would represent a price of 126.40, which is a decrease of -0.10%.

Below was the last reported quarterly diluted earnings per share:

1stQtr of 2019 (Reported on 05/07/2019): 1.11
4thQtr of 2018 (Reported on 02/13/2019): 1.21
3rdQtr of 2018 (Reported on 11/07/2018): 1.22
2ndQtr of 2018 (Reported on 08/08/2018): 1.10
1stQtr of 2018 (Reported on 05/10/2018): 1.08

Base on our calculations, the intrinsic value per share is 130.06, which means it is possibly undervalued and has a margin of safety of 2.72%.

Indicators to Watch:

Short-interest was 1,276,971, which was 2.62% of shares outstanding. The short-interest ratio or days-to-cover ratio was 3.64. This stock has some short interest, but it may be normal and no cause for concern if long the position.

The current calculated beta is 1.05.

Business Wire:  Medical Properties Trust Acquires 46% Interest in $900 Million Portfolio of Premier Swiss Hospitals

Fundamental Indicators:

Based on last reported financials, the company’s return on equity is 18.79%, return on assets is 6.87%, profit margin is 9.80%, price-to-sales is 2.53 and price-to-book is 4.30.

Company Scores:

All scores are out of six:
 2  :Valuation Score
 4  :Past Performance Score
 3  :Financial Strength Score
 4  :Future Growth Score
 0  :Dividend Score
 3  :Overall Score

John Jones
Worked for several Wall Street firms: Salomon Smith Barney, UBS, and Charles Schwab. Has developed skills and gained extensive experience over the years that is used today to uncover winning penny stocks.Also was an attorney for small businesses in Scottsdale, Arizona. That experience and understanding of law provides a unique perspective and edge in discovering quality companies in various industries.